Zerlasiran

Zerlasiran is an apolipoprotein A (ApoA) synthesis reducer[1].

Product Specifications

CAS Number

[2646703-64-0]

Product Name Alternative

SLN360

UNSPSC

12352208

Target

Apolipoprotein; Small Interfering RNA (siRNA)

Type

Oligonucleotides

Related Pathways

Epigenetics; Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/zerlasiran.html

Solubility

10 mM in DMSO

Smiles

[Zerlasiran]

Molecular Formula

C443H594F12N144O277P40S10

Molecular Weight

14155.81

References & Citations

[1]Rider DA, Eisermann M, Löffler K, et al. Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease. Atherosclerosis. 2022;349:240-247. |[2]Nissen SE, Wolski K, Watts GF, et al. Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein (a) : A Randomized Clinical Trial. JAMA. 2024;331 (18) :1534-1543.